Work

A Case Report of a Multisystemic Immune‐Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha‐1

Year: 2026

Type: article

Abstract: To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure. By analyzing the course of treatment and regression, the risks and management strategies of combining immune checkpoint inhibitors (ICIs) with immunomodulators are discussed in the light of the literature. This highlights the need for clinical vigilance against possible immune overactivation triggered by combination therapy.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.72025

Authors: Ting Li, Bao‐Liang Wu, Cai‐Long Yu, Liang‐Yan Jin

Institution: Hangzhou Xixi hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820